March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Acalabrutinib Regimens Improve PFS in Treatment-Naïve Patients with CLLDecember 8th 2019
Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia
FDA Grants Breakthrough Therapy Designation to Abatacept for Acute GVHD PreventionDecember 4th 2019
The FDA granted a breakthrough therapy designation to abatacept for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.
NCCN Issues Guidelines for Stem Cell TransplantationNovember 4th 2019
The National Comprehensive Cancer Network recently issued new guidelines on best practices in evaluating patients for hematopoietic cell transplantation, as well as how to manage complications associated with the procedure.
Could Pre-Transplant PET/CT Deauville Score Predict Treatment Failure in R/R DLBCL?August 29th 2019
Researchers looked at the pre-transplant PET/CT Deauville scores of patients with relapsed or refractory diffuse large B-cell lymphoma treated with R-DHAC to see if patients with a higher score had a higher risk for treatment failure.
Triple Mutation More Deadly in Favorable-Risk AMLAugust 22nd 2019
Researchers utilized a targeted next-generation sequencing (NGS) panel developed at Oregon Health & Science University to assess the clearance of mutations after therapy, clonal evolution at relapse, and combinations of mutations.
Examining MRD-Driven Consolidation with Rituximab in Early Stage Follicular LymphomaAugust 12th 2019
Patients with follicular lymphoma who were minimal residual disease-positive after undergoing involved field radiation therapy were given rituximab to see how it affected progression-free survival.
Therapy Options in Treating Acute Lymphoblastic Leukemia in AdultsJuly 16th 2019
ONCOLOGY discussed therapy options for adult acute lymphoblastic leukemia with Dr. Elias Jabbour, MD, Professor of Medicine in the Department of Leukemia at the MD Anderson Cancer Center in Houston, Texas.